Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Brain copper may protect from cognitive decline and Alzheimer’s disease pathology: a community-based study

Abstract

Copper is an essential micronutrient for brain health and dyshomeostasis of copper could have a pathophysiological role in Alzheimer’s disease (AD), however, there are limited data from community-based samples. In this study, we investigate the association of brain copper (assessed using ICP-MS in four regions -inferior temporal, mid-frontal, anterior cingulate, and cerebellum) and dietary copper with cognitive decline and AD pathology burden (a quantitative summary of neurofibrillary tangles, diffuse and neuritic plaques in multiple brain regions) at autopsy examination among deceased participants (N = 657; age of death: 90.2(±6.2)years, 70% women, 25% APOE-ɛ4 carriers) in the Rush Memory and Aging Project. During annual visits, these participants completed cognitive assessments using a 19-test battery and dietary assessments (using a food frequency questionnaire). Regression, linear mixed-effects, and logistic models adjusted for age at death, sex, education, and APOE-ε4 status were used. Higher composite brain copper levels were associated with slower cognitive decline (β(SE) = 0.028(0.01), p = 0.001) and less global AD pathology (β(SE) = −0.069(0.02), p = 0.0004). Participants in the middle and highest tertile of dietary copper had slower cognitive decline (T2vs.T1: β = 0.038, p = 0.0008; T3vs.T1: β = 0.028, p = 0.01) than those in the lowest tertile. Dietary copper intake was not associated with brain copper levels or AD pathology. Associations of higher brain copper levels with slower cognitive decline and with less AD pathology support a role for copper dyshomeostasis in AD pathogenesis and suggest that lower brain copper may exacerbate or indicate disease severity. Dietary and brain copper are unrelated but dietary copper is associated with slower cognitive decline via an unknown mechanism.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Brain copper levels and cognitive decline.
Fig. 2: Brain copper levels and AD pathology.

References

  1. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273:12817–26.

    Article  CAS  PubMed  Google Scholar 

  2. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000;75:1219–33.

    Article  CAS  PubMed  Google Scholar 

  3. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease. J Struct Biol. 2006;155:30–7.

    Article  CAS  PubMed  Google Scholar 

  4. Squitti R, Faller P, Hureau C, Granzotto A, White AR, Kepp KP. Copper Imbalance in Alzheimer’s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. J Alzheimer’s Dis: JAD. 2021;83:23–41.

    Article  CAS  PubMed  Google Scholar 

  5. Li DD, Zhang W, Wang ZY, Zhao P. Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer’s Disease: A Meta-Analysis of Case-Control Studies. Front Aging Neurosci. 2017;9:300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, et al. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci. 2003;100:14193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer’s disease preclinical studies. Embo j. 2017;36:2473–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Itoh S, Ozumi K, Kim HW, Nakagawa O, McKinney RD, Folz RJ, et al. Novel mechanism for regulation of extracellular SOD transcription and activity by copper: role of antioxidant-1. Free Radic Biol Med. 2009;46:95–104.

    Article  CAS  PubMed  Google Scholar 

  9. Sensi SL, Granzotto A, Siotto M, Squitti R. Copper and Zinc Dysregulation in Alzheimer’s Disease. Trends Pharm Sci. 2018;39:1049–63.

    Article  CAS  PubMed  Google Scholar 

  10. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis. 1999;6:221–30.

    Article  CAS  PubMed  Google Scholar 

  11. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol. 2006;63:1085–8.

    Article  PubMed  Google Scholar 

  12. Wang X, Li X, Xing Y, Wang W, Li S, Zhang D, et al. Threshold Effects of Total Copper Intake on Cognitive Function in US Older Adults and the Moderating Effect of Fat and Saturated Fatty Acid Intake. J Acad Nutr Diet. 2021;121:2429–42.

    Article  PubMed  Google Scholar 

  13. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimer’s Dis: JAD. 2018;64:S161–S189.

    Article  PubMed  Google Scholar 

  14. Morris MC. Validity and Reproducibility of a Food Frequency Questionnaire by Cognition in an Older Biracial Sample. Am J Epidemiol. 2003;158:1213–7.

    Article  PubMed  Google Scholar 

  15. Wilson RS, Boyle PA, Yu L, Barnes LL, Sytsma J, Buchman AS, et al. Temporal course and pathologic basis of unawareness of memory loss in dementia. Neurology 2015;85:984–91.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837–44.

    Article  CAS  PubMed  Google Scholar 

  17. Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, et al. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85:114–24.

    Article  CAS  PubMed  Google Scholar 

  18. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378–84.

    Article  PubMed  Google Scholar 

  19. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–86.

    Article  CAS  PubMed  Google Scholar 

  20. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239–59.

    Article  CAS  PubMed  Google Scholar 

  21. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging. 1997;18:S1–2.

    Google Scholar 

  22. Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, et al. TOMM40'523 variant and cognitive decline in older persons with APOE epsilon3/3 genotype. Neurology 2017;88:661–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, et al. Decision rules guiding the clinical diagnosis of Alzheimer’s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006;27:169–76.

    Article  PubMed  Google Scholar 

  24. Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc. 2005;11:400–7.

    Article  PubMed  Google Scholar 

  25. Buchman AS, Boyle PA, Wilson RS, Bienias JL, Bennett DA. Physical activity and motor decline in older persons. Muscle Nerve. 2007;35:354–62.

    Article  CAS  PubMed  Google Scholar 

  26. Agarwal P, Wang Y, Buchman AS, Holland TM, Bennett DA, Morris MC. Dietary antioxidants associated with slower progression of parkinsonian signs in older adults. Nutritional Neurosci. 2020;25:550–557. https://doi.org/10.1080/1028415X.2020.1769411.

    Article  Google Scholar 

  27. Willett WC Implication of Total Energy Intake fo Epidemiological Analyses, vol. Third Edition 2013, 260-286pp.

  28. Magaki S, Raghavan R, Mueller C, Oberg KC, Vinters HV, Kirsch WMIron. copper, and iron regulatory protein 2 in Alzheimer’s disease and related dementias. Neurosci Lett. 2007;418:72–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, McLean C, et al. Decreased copper in Alzheimer’s disease brain is predominantly in the soluble extractable fraction. Int J Alzheimers Dis. 2013;2013:623241–623241.

    PubMed  PubMed Central  Google Scholar 

  30. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer’s disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94:296–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gerber H, Wu F, Dimitrov M, Garcia Osuna GM, Fraering PC. Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production. J Biol Chem. 2017;292:3751–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Acevedo KM, Hung YH, Dalziel AH, Li Q-X, Laughton K, Wikhe K, et al. Copper promotes the trafficking of the amyloid precursor protein. J Biol Chem. 2011;286:8252–62.

    Article  CAS  PubMed  Google Scholar 

  33. Cater MA, McInnes KT, Li QX, Volitakis I, La Fontaine S, Mercer JF, et al. Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. Biochem J. 2008;412:141–52.

    Article  CAS  PubMed  Google Scholar 

  34. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43–55.

    Article  CAS  PubMed  Google Scholar 

  35. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, et al. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer’s disease. PloS One. 2011;6:e17669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bayer TA, Schäfer S, Simons A, Kemmling A, Kamer T, Tepest R, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci. 2003;100:14187–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779–86.

    Article  CAS  PubMed  Google Scholar 

  38. Diouf I, Bush AI, Ayton S. Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology. Neurobiol Dis. 2020;139:104810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Giacoppo S, Galuppo M, Calabrò RS, D’Aleo G, Marra A, Sessa E, et al. Heavy metals and neurodegenerative diseases: an observational study. Biol Trace Elem Res. 2014;161:151–60.

    Article  CAS  PubMed  Google Scholar 

  40. Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial. J Neural Transm (Vienna). 2008;115:1651–9.

    Article  CAS  Google Scholar 

  41. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004;63:1705–7.

    Article  CAS  PubMed  Google Scholar 

  42. Lamtai M, Zghari O, Ouakki S, Marmouzi I, Mesfioui A, El Hessni A, et al. Chronic copper exposure leads to hippocampus oxidative stress and impaired learning and memory in male and female rats. Toxicol Res. 2020;36:359–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yu H, Jiang X, Lin X, Zhang Z, Wu D, Zhou L, et al. Hippocampal Subcellular Organelle Proteomic Alteration of Copper-Treated Mice. Toxicological Sci: Off J Soc Toxicol. 2018;164:250–63.

    Article  CAS  Google Scholar 

  44. Yu J, Luo X, Xu H, Ma Q, Yuan J, Li X, et al. Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of Alzheimer’s disease using proteomic analysis. J Alzheimer’s Dis: JAD. 2015;44:455–69.

    Article  CAS  PubMed  Google Scholar 

  45. Lin X, Wei G, Huang Z, Qu Z, Huang X, Xu H, et al. Mitochondrial proteomic alterations caused by long-term low-dose copper exposure in mouse cortex. Toxicol Lett. 2016;263:16–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the participants and the staff of Rush Memory and Aging Project and the Rush Alzheimer’s Disease Center. We also thank the biostatisticians Yamin Wang and Woojeong Bang who worked on this project.

Funding

This study was supported by grants from the National Institute of Health (R01AG054057 (JAS, AIB), R01AG017917 (DAB), and the National Health and Medical Research Council of Australia (SA, AIB). None of the funding sources have any role in data analysis, interpretation, and manuscript preparation.

Author information

Authors and Affiliations

Authors

Contributions

PA, SA, AIB, DAB and JAS: conceptualization, PA, SA, SEL: data analysis PA: manuscript preparation, edits and revisions, SA, SA, KD, DAB, LLB, SEL, AIB, and JAS: manuscript review and editing, SA, AIB, and JAS: supervision, SA, DAB, AIB, and JAS: funding acquisition.

Corresponding author

Correspondence to Julie A. Schneider.

Ethics declarations

Competing interests

AIB Holds equity: Alterity Biotechnology Ltd, Cogstate Ltd, Mesoblast Ltd, Collaborative Medicinal Development LLC. Paid consultant: Collaborative Medicinal Development Pty Ltd. Julie A Schneider and other  authors report no competing interests.

Additional information

The authors dedicate this manuscript to Dr. Martha Clare Morris, who passed away during its drafting.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Agarwal, P., Ayton, S., Agrawal, S. et al. Brain copper may protect from cognitive decline and Alzheimer’s disease pathology: a community-based study. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01802-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41380-022-01802-5

Search

Quick links